Look for:

Our offer for

GLAXOSMITHKLINE ORD GBP0.25


ISIN:
GB0009252882
WKN:
0925288
2022/01/18 19:31:22
Price
20.30 EUR
Difference 0.00% (0.00)

General attributes

ISINGB0009252882
SymbolGSK
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)94,659 EUR
BenchmarkFTSE 100

Market data

Bid (Bid size)-
Ask (Ask size)-
Open20.35 EUR
High20.55 EUR
Low20.25 EUR
Close (prev. day)20.30 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades13
Last size0

Futures and Options

Related Futures39
Related Options-

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2022/01/18 19:31:22
Price
20.30 EUR
Difference 0.00% (0.00)

General attributes

ISINGB0009252882
SymbolGSK
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)94,659 EUR
BenchmarkFTSE 100

Market data

Bid (Bid size)-
Ask (Ask size)-
Open20.35 EUR
High20.55 EUR
Low20.25 EUR
Close (prev. day)20.30 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades13
Last size0

Performance and Risk

6m1Y3Y
Perf (%)+20.98%+28.53%+18.41%
Perf (abs.)+3.52+4.51+3.16
Beta0.590.610.67
Volatility17.9017.6320.82
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)19.89 EUR (4)
Ø price 30 days | Ø volume 30 days (pcs.)19.25 EUR (63)
Ø price 100 days | Ø volume 100 days (pcs.)17.94 EUR (38)
Ø price 250 days | Ø volume 250 days (pcs.)16.74 EUR (116)
YTD High | date20.75 EUR (2022/01/17)
YTD Low | date19.10 EUR (2022/01/03)
52 Weeks High | date20.75 EUR (2022/01/17)
52 Weeks Low | date14.01 EUR (2021/03/01)

All listings for GLAXOSMITHKLINE ORD GBP0.25

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2022/01/1817:3520.60 EUR2.83260
Tradegate2022/01/1822:2620.50 EUR1.51255
Stuttgart2022/01/1817:5820.55 EUR0.3125
SIX Swiss Exchange2020/04/2117:3621.50 CHF0.001
Munich2022/01/1808:0120.45 EUR0.011
London Stock Exchange2022/01/1817:381,703.60 GBp14,366.2118,255
Hanover2022/01/1808:0120.40 EUR0.001
Hamburg2022/01/1813:3920.40 EUR0.002
Frankfurt2022/01/1818:0620.40 EUR0.0912
FINRA other OTC Issues2022/01/1820:2123.399 USD0.0710
Duesseldorf2022/01/1819:3120.30 EUR0.0013
Berlin2022/01/1808:0820.40 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2549&ID_TYPE_IMAGE_LOGO=2

Contact Details

GLAXOSMITHKLINE PLC
- -
980 Great West Road - TW8 9GS Middlesex
Telefon: 44-20-8047-5000
Fax: 44-20-8047-7807
E-mail: -

PDF Downloads

Company report: GLAXOSMITHKLINE ORD GBP0.25PDF Download

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Members of Management Board

Emma WalmsleyChairman of Managing Board
Christopher CorsicoMember of Executive Committee
Jon EllisMember of Executive Committee
Neil BarnesMember of Executive Committee
Rab PrinjhaMember of Executive Committee
Romulo ColindresMember of Executive Committee
Amy AltshulMember of Executive Committee
Brian McNamaraMember of Executive Committee
Deborah WaterhouseMember of Executive Committee
Diana ConradMember of Executive Committee
James FordMember of Executive Committee
Karenann TerrellMember of Executive Committee
Kevin SinMember of Executive Committee
Luke MielsMember of Executive Committee
Marc JonesMember of Executive Committee
María Cristina de Luna BasagoitiMember of Executive Committee
Maya Martinez-DavisMember of Executive Committee
Philip ThomsonMember of Executive Committee
Regis Jean-Pierre SimardMember of Executive Committee
Roger ConnorMember of Executive Committee
Sarah Elton-FarrMember of Executive Committee
Sarah-Jane HallMember of Executive Committee
Seok Kian TayMember of Executive Committee
Tatyana StanevaMember of Executive Committee
Tony WoodMember of Executive Committee

Board of directors

Jonathan SymondsChairman of Supervisory Board
Anne BealMember of Supervisory Board
Hal BarronMember of Supervisory Board
Harry DietzMember of Supervisory Board
Jesse GoodmanMember of Supervisory Board
Laurie GlimcherMember of Supervisory Board
Charles BancroftMember of Supervisory Board
Iain MackayMember of Supervisory Board
Lynn ElsenhansMember of Supervisory Board
Manvinder Singh BangaMember of Supervisory Board
Urs RohnerMember of Supervisory Board
Vivienne CoxMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer